Advertisement

Systemic Treatment of Early Breast Cancer by Hormonal, Cytotoxic, or Immune Therapy:133 Randomised Trials involoving 31 000 Recurrences and 24 000 Deaths Among 75 000 Women (Summary)

  • Early Breast Cancer Trialists’ Collaborative Group
  • R. Peto
Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 127)

Abstract

In a worldwide collaboration, information was sought and centrally checked on mortality and recurrence for each woman in any randomised trial that began before 1985 of any aspect of systemic adjuvant therapy for early breast cancer. Checked data were available for 75 000 women (about 90% of those ever randomised), of whom 32% had died and another 10% had experienced recurrence. The parts now reviewed include 30000 women in tamoxifen trials, 3000 in ovarian ablation trials, 11000 in polychemotherapy trials, 15000 in other chemotherapy comparisons, and 6000 in immunotherapy trials.

Keywords

Breast Cancer Annual Rate Early Breast Cancer Collaborative Group Contralateral Breast Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Berlin · Heidelberg 1993

Authors and Affiliations

  • Early Breast Cancer Trialists’ Collaborative Group
  • R. Peto

There are no affiliations available

Personalised recommendations